DDInter336 DDInter717
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998. Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients typically display delayed development and neurocognitive impairment.[A214694, A214709, A214712, A214715] Fenfluramine is a serotonergic phenethylamine originally used as an appetite suppressant until concerns regarding cardiotoxicity in obese patients lead to its withdrawal from the market in 1997.[A214694, A214718, A11906] Through its ability to modulate neurotransmission, fenfluramine has reemerged as an effective therapy against pharmacoresistant seizures, such as those involved in Dravet syndrome.[A214688, A214691, A214700] Fenfluramine was granted initial FDA approval in 1973 prior to its withdrawal; it was granted a new FDA approval on June 25, 2020, for treatment of patients with Dravet syndrome and Lennox-Gastaut syndrome through the restricted FINTEPLA REMS program. It is currently sold under the name FINTEPLA® by Zogenix INC.
Celecoxib {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Tolterodine
Tolterodine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fenfluramine
Celecoxib {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Nateglinide
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fenfluramine
Celecoxib {u} (Compound) causes {v} (Side Effect) Dry mouth
Dry mouth {u} (Side Effect) is caused by {v} (Compound) Tolterodine
Tolterodine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fenfluramine
Celecoxib {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Indomethacin
Indomethacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fenfluramine
Celecoxib {u} (Compound) causes {v} (Side Effect) Dry mouth
Dry mouth {u} (Side Effect) is caused by {v} (Compound) Regorafenib
Regorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fenfluramine
Celecoxib {u} (Compound) causes {v} (Side Effect) Abdominal pain
Abdominal pain {u} (Side Effect) is caused by {v} (Compound) Tolmetin
Tolmetin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fenfluramine
Celecoxib {u} (Compound) causes {v} (Side Effect) Influenza-like symptoms
Influenza-like symptoms {u} (Side Effect) is caused by {v} (Compound) Citalopram
Citalopram {u} may lead to a major life threatening interaction when taken with {v} Fenfluramine
Celecoxib {u} (Compound) causes {v} (Side Effect) Influenza-like symptoms
Influenza-like symptoms {u} (Side Effect) is caused by {v} (Compound) Dolasetron
Dolasetron {u} may lead to a major life threatening interaction when taken with {v} Fenfluramine
Celecoxib {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Fluvoxamine
Fluvoxamine {u} may lead to a major life threatening interaction when taken with {v} Fenfluramine
Celecoxib {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Dexfenfluramine
Dexfenfluramine {u} may lead to a major life threatening interaction when taken with {v} Fenfluramine
Celecoxib (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Tolterodine (Compound) and Tolterodine may cause a minor interaction that can limit clinical effects when taken with Fenfluramine
Celecoxib (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nateglinide (Compound) and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine
Celecoxib (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Tolterodine (Compound) and Tolterodine may cause a minor interaction that can limit clinical effects when taken with Fenfluramine
Celecoxib (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Indomethacin (Compound) and Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine
Celecoxib (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Regorafenib (Compound) and Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine
Celecoxib (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Tolmetin (Compound) and Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine
Celecoxib (Compound) causes Influenza-like symptoms (Side Effect) and Influenza-like symptoms (Side Effect) is caused by Citalopram (Compound) and Citalopram may lead to a major life threatening interaction when taken with Fenfluramine
Celecoxib (Compound) causes Influenza-like symptoms (Side Effect) and Influenza-like symptoms (Side Effect) is caused by Dolasetron (Compound) and Dolasetron may lead to a major life threatening interaction when taken with Fenfluramine
Celecoxib (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Fluvoxamine (Compound) and Fluvoxamine may lead to a major life threatening interaction when taken with Fenfluramine
Celecoxib (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Dexfenfluramine (Compound) and Dexfenfluramine may lead to a major life threatening interaction when taken with Fenfluramine